Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Krystal Biotech Inc (NASDAQ: KRYS) was $199.88 for the day, down -1.66% from the previous closing price of $203.26. In other words, the price has decreased by -$1.66 from its previous closing price. On the day, 0.68 million shares were traded. KRYS stock price reached its highest trading level at $204.04 during the session, while it also had its lowest trading level at $194.915.
Ratios:
Our analysis of KRYS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.93 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 35.00. For the most recent quarter (mrq), Quick Ratio is recorded 9.73 and its Current Ratio is at 10.14. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Jefferies on March 05, 2025, initiated with a Buy rating and assigned the stock a target price of $245.
On August 06, 2024, Citigroup Downgraded its rating to Neutral which previously was Buy and also upped its target price recommendation from $195 to $204.
On November 20, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $160.Goldman initiated its Buy rating on November 20, 2023, with a $160 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 14 ’25 when Krishnan Suma sold 13,435 shares for $150.30 per share. The transaction valued at 2,019,225 led to the insider holds 1,443,276 shares of the business.
Krishnan Suma sold 13,400 shares of KRYS for $2,014,015 on Jul 14 ’25. The President, R&D now owns 1,512,529 shares after completing the transaction at $150.30 per share. On Jul 15 ’25, another insider, Krishnan Suma, who serves as the President, R&D of the company, sold 3,084 shares for $151.01 each. As a result, the insider received 465,700 and left with 1,509,445 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KRYS now has a Market Capitalization of 5785122816 and an Enterprise Value of 5074466304. As of this moment, Krystal’s Price-to-Earnings (P/E) ratio for their current fiscal year is 29.98, and their Forward P/E ratio for the next fiscal year is 26.18. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.60. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.53 while its Price-to-Book (P/B) ratio in mrq is 5.09. Its current Enterprise Value per Revenue stands at 13.598 whereas that against EBITDA is 31.78.
Stock Price History:
The Beta on a monthly basis for KRYS is 0.49, which has changed by 0.09603667 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, KRYS has reached a high of $212.98, while it has fallen to a 52-week low of $122.80. The 50-Day Moving Average of the stock is 15.83%, while the 200-Day Moving Average is calculated to be 25.46%.
Shares Statistics:
KRYS traded an average of 326.54K shares per day over the past three months and 347190 shares per day over the past ten days. A total of 28.98M shares are outstanding, with a floating share count of 24.91M. Insiders hold about 14.10% of the company’s shares, while institutions hold 93.65% stake in the company. Shares short for KRYS as of 1760486400 were 2889558 with a Short Ratio of 8.85, compared to 1757894400 on 3603723. Therefore, it implies a Short% of Shares Outstanding of 2889558 and a Short% of Float of 16.73.
Earnings Estimates
As of right now, 1.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $1.5, with high estimates of $2.13 and low estimates of $0.87.
Analysts are recommending an EPS of between $5.34 and $4.9 for the fiscal current year, implying an average EPS of $5.12. EPS for the following year is $8.6, with 4.0 analysts recommending between $9.79 and $6.7.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 7 analysts. It ranges from a high estimate of $116.96M to a low estimate of $100.06M. As of. The current estimate, Krystal Biotech Inc’s year-ago sales were $91.14MFor the next quarter, 7 analysts are estimating revenue of $120.69M. There is a high estimate of $127.6M for the next quarter, whereas the lowest estimate is $110M.
A total of 9 analysts have provided revenue estimates for KRYS’s current fiscal year. The highest revenue estimate was $398.99M, while the lowest revenue estimate was $381.53M, resulting in an average revenue estimate of $388.53M. In the same quarter a year ago, actual revenue was $290.51MBased on 10 analysts’ estimates, the company’s revenue will be $562.1M in the next fiscal year. The high estimate is $634.8M and the low estimate is $446.35M.
